UPDATE : Monday, September 7, 2020
상단여백
Hanmi, Sanofi revise accord on co-developing diabetes drug
Hanmi Pharmaceutical said it has signed a revised agreement with Sanofi to ...
by Lee Han-soo  |  2019-06-25 17:36
라인
‘Imbruvica raised survival rate of mantle cell lymphoma patients’
“Imbruvica works better than any other existing chemotherapy in relapsed an...
by Kim Yun-mi  |  2019-06-25 15:34
라인
CHA Biotech to transfer SCRMI’s shares, technology to AIRM
CHA Biotech said that it would transfer shares and technologies of Stem Cel...
by Lee Han-soo  |  2019-06-25 15:25
라인
Regulator OKs P3 trial for Eisai's Alzheimer treatment
The Ministry of Food and Drug Safety has approved the phase 3 clinical tria...
by Lee Han-soo  |  2019-06-25 14:09
라인
Novartis’ Cosentyx shows durable, comprehensive treatment for psoriatic disease
Novartis has released new data on five-year long-term immunogenicity and in...
by Lee Han-soo  |  2019-06-25 14:09
라인
Celltrion denies delay in local license application for HIV drug Temixys
The Ministry of Food and Drug Safety and Celltrion said rumors about the dr...
by Lee Hye-seon  |  2019-06-25 10:56
라인
Latecomer experimental drug no better than Dupixent in trial
Pharmaceutical firms have strived to make latecomer drugs to beat Dupixent ...
by Kim Yun-mi  |  2019-06-24 15:49
라인
Daewoong wins new indications for Nabota
Daewoong Pharmaceutical's Nabota, its botulinum toxin (BTX) strain, has...
by Lee Han-soo  |  2019-06-24 14:47
라인
Kang Stem Biotech completes P3 trials for stem cell-based atopy treatment
Kang Stem Biotech has completed the subject evaluation of phase 3 clinical ...
by Lee Han-soo  |  2019-06-24 12:19
라인
Anti-cancer Sutene could cause central nervous system abnormality in fetus
Pfizer Korea’s renal cancer treatments Sutene Cap. (ingredient: sunitinib m...
by Lee Hye-seon  |  2019-06-24 11:35
라인
Boryung calls off ￦83-billion supply contract in Jordan
Boryung Pharmaceutical said that it has canceled its contract to supply 83 ...
by Lee Han-soo  |  2019-06-21 18:00
라인
MSD’s antibiotic Zerbaxa fails to get insurance coverage
MSD Korea’s antibiotic drug Zerbaxa Inj. failed to receive insurance covera...
by Kim Eun-young  |  2019-06-21 14:13
라인
‘Customized strategies needed for fast-changing Chinese drug regulation’
Foreign drugmakers need to make the most of China’s revised drug regulation...
by Jeong Sae-im  |  2019-06-21 14:12
라인
Off-label use of Mabthera Inj. denied
The Health Insurance Review and Assessment Service (HIRA) said it has disap...
by Kim Yun-mi  |  2019-06-20 15:49
라인
‘Korean cancer researchers have risen to world-class level’
The Korean Cancer Study Group (KCSG) said Korean institutions and researche...
by Kim Yun-mi  |  2019-06-20 15:04
라인
AbbVie unveils data from upadacitinib phase-3 studies of rheumatoid arthritis
AbbVie has recently announced the latest results from the phase 3 clinical ...
by Lee Han-soo  |  2019-06-19 16:27
라인
Hanmi launches osteoarthritis injection in US
Hanmi Pharmaceutical has launched Hyalrheuma, an hyaluronic acid (HA)- base...
by Lee Han-soo  |  2019-06-19 14:52
라인
Genexine to merge with Toolgen
Genexine and Toolgen have agreed to merge their businesses and become ToolG...
by Lee Han-soo  |  2019-06-19 14:24
라인
‘Keytruda will become most sold orphan drug worldwide by 2024’
The Korea Health Industry Development Institute (KHIDI) recently forecast t...
by Kim Yun-mi  |  2019-06-19 11:11
라인
ABL Bio releases latest data on Parkinson's disease treatment
ABL Bio said that it has presented its latest research result for ABL301, a...
by Lee Han-soo  |  2019-06-18 17:16
-이전4142-
176 civic groups furious over government-doctors deal176 civic groups furious over government-doctors deal
여백
Most viewed
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top